FyoniBio and adivo GmbH Sign a Service Agreement Covering the Generation of a Production Cell Line for Their Canine Therapeutic mAb Candidate
FyoniBio and adivo GmbH have entered a service agreement to advance adivo’s leading therapeutic canine mAb candidate into first-in-animal studies. Using its CHOnamite® platform, FyoniBio will develop a robust production cell line tailored to adivo’s species-specific antibody format—supporting high yield and quality for veterinary clinical development.
